Market:

There are over 300 life-threatening primary immune deficiencies for which there are limited treatment options currently available.

Technology:

ImmunoVec has developed a platform for the generation of lentiviral vectors that are specifically engineered for each disease target. We are able to modify the patient’s own blood stem cells and introduce a highly regulated, functional copy of the gene of interest. These gene-modified blood stem cells have the ability to give rise to a fully functional immune system, without the risk of graft-versus-host disease.

Advantages:

• Endogenous expression of therapeutic gene
• Optimal gene transfer
• Novel genetic elements

Development Stage:

• Pre-Clinical

Patents Issued:

• Coming Soon

Select Publications:

• Coming Soon

Contact:

Website: www.immunovec.com